The burden of (drug-)drug-gene interactions within the Lifelines Cohort population as part of the PharmLines Initiative
In recent years, there has been substantial progress in the field of pharmacogenetics. In general, knowledge of pharmacogenetic relevant variants in patients DNA can help in optimizing the choice of drugs and in finding the appropriate dose. Not surprisingly therefore, an increasing number of commercial and non-commercial pharmacogenetic tests are becoming available.
The research aims of this project are: 1) to determine the prevalence of relevant drug-gene interactions (DGIs), i.e. those already selected by the Dutch Pharmacogenetics Working Group (DPWG) and medical context, and 2) to determine the burden and impact of pharmacogenetics on drug-drug interactions (DDIs) and drug-drug-gene interactions (DDGIs). Both objectives are studied in a selection of the genotyped Lifelines Cohort population for which detailed medication data is available through linkage with the University of Groningen prescription database IADB.nl.